Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
12ATC + 5FU + GM-CSF + IFN-alpha in Metastatic RCC or CRC
NCT00030342Phase 2Completed
- Sponsor
- St. Luke's Medical Center
- Start
- Nov 2001
- Primary completion
- Oct 2007
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of interleukin-12-primed activated T cells in renal cell carcinoma (RCC), colorectal carcinoma (CRC), sponsored by St. Luke's Medical Center. Started Nov 2001; status: completed.
02
Drugs
interleukin-12-primed activated T cells
03
Conditions
renal cell carcinoma (RCC)colorectal carcinoma (CRC)
Beyond the preview
Go deeper on NCT00030342.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00030342.